This logic has manifested in the newly released guidance to companies interested in pursuing a broad listing for cancer immunotherapies. An expectation of no net cost. Patients, you waited nine years for this, and it was granted on the basis that your treatment cost the government nothing. That is what your life is worth.
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - - Latest News -
LTR Pharma secures national US manufacturing and fulfilment partner
July 21, 2026 - - Latest News -
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 - - Latest News -
'Our access. Our medicines. Our vaccines. Our medical technology'
July 21, 2026 - - Latest News -
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News

